ResMed Inc. (RMD)
NYSE$221.056+0.81 (0.37%)
Market Cap
$32.35B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
812 of 924
Rank in Industry
43 of 47
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
RMD Insider Trading Activity
RMD Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $57,043,960 | 44 | 100 |
Related Transactions
| Drexler Karen | director | 0 | $0 | 1 | $91,341 | $-91,341 |
| De Witte Jan | director | 0 | $0 | 2 | $276,637 | $-276,637 |
| Rider Michael J | Global General Counsel | 0 | $0 | 6 | $286,681 | $-286,681 |
| FARRELL PETER C | director | 0 | $0 | 7 | $3.34M | $-3.34M |
| Sandercock Brett | Chief Financial Officer | 0 | $0 | 11 | $5.04M | $-5.04M |
| Ghoshal Kaushik | President, SaaS Business | 0 | $0 | 5 | $8.92M | $-8.92M |
| Leong Justin | President, Asia Latin America | 0 | $0 | 2 | $11.92M | $-11.92M |
| Farrell Michael J. | Chief Executive Officer | 0 | $0 | 10 | $27.17M | $-27.17M |
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software …
Insider Activity of ResMed Inc.
Over the last 12 months, insiders at ResMed Inc. have bought $0 and sold $57.04M worth of ResMed Inc. stock.
On average, over the past 5 years, insiders at ResMed Inc. have bought $0 and sold $31.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $424,500 was made by SULPIZIO RICHARD (director) on 2006‑08‑21.
List of Insider Buy and Sell Transactions, ResMed Inc.
| 2025-03-10 | Sale | Sandercock Brett | Chief Financial Officer | 1,000 0.0007% | $230.36 | $230,360 | -6.10% | |
| 2025-03-10 | Sale | Ghoshal Kaushik | Chief Commercial Officer, SaaS | 9,745 0.0067% | $239.31 | $2.33M | -6.10% | |
| 2025-03-07 | Sale | Farrell Michael J. | Chief Executive Officer | 8,009 0.0054% | $229.20 | $1.84M | -3.47% | |
| 2025-03-05 | Sale | FARRELL PETER C | director | 2,000 0.0014% | $227.71 | $455,420 | +0.40% | |
| 2025-03-03 | Sale | Ghoshal Kaushik | Chief Commercial Officer, SaaS | 9,113 0.0063% | $235.40 | $2.15M | -3.62% | |
| 2025-03-03 | Sale | Rider Michael J | Global General Counsel | 64 <0.0001% | $234.10 | $14,982 | -3.62% | |
| 2025-02-10 | Sale | Sandercock Brett | Chief Financial Officer | 1,000 0.0007% | $238.98 | $238,980 | -2.73% | |
| 2025-02-07 | Sale | Farrell Michael J. | Chief Executive Officer | 8,009 0.0054% | $236.77 | $1.9M | -2.03% | |
| 2025-02-05 | Sale | FARRELL PETER C | director | 2,000 0.0014% | $242.11 | $484,220 | -4.24% | |
| 2025-02-03 | Sale | Rider Michael J | Global General Counsel | 64 <0.0001% | $242.42 | $15,515 | -3.27% | |
| 2025-01-08 | Sale | Sandercock Brett | Chief Financial Officer | 1,000 0.0007% | $234.04 | $234,040 | -0.91% | |
| 2025-01-02 | Sale | FARRELL PETER C | director | 2,000 0.0014% | $230.99 | $461,980 | +2.71% | |
| 2025-01-02 | Sale | Rider Michael J | Global General Counsel | 75 <0.0001% | $230.99 | $17,324 | +2.71% | |
| 2024-12-09 | Sale | Sandercock Brett | Chief Financial Officer | 1,000 0.0007% | $244.23 | $244,230 | -4.37% | |
| 2024-12-04 | Sale | FARRELL PETER C | director | 2,000 0.0014% | $245.65 | $491,300 | -4.37% | |
| 2024-12-02 | Sale | Rider Michael J | Global General Counsel | 74 <0.0001% | $248.91 | $18,419 | -3.57% | |
| 2024-11-27 | Sale | Farrell Michael J. | Chief Executive Officer | 2,000 0.0014% | $249.66 | $499,330 | -5.27% | |
| 2024-11-22 | Sale | Leong Justin | Chief Product Officer | 6,160 0.0042% | $243.09 | $1.5M | -3.07% | |
| 2024-11-12 | Sale | De Witte Jan | director | 796 0.0005% | $248.81 | $198,053 | -4.33% | |
| 2024-11-08 | Sale | Sandercock Brett | Chief Financial Officer | 1,000 0.0007% | $249.00 | $249,000 | -6.20% |
Total: 585
*Gray background shows transactions not older than one year
Insider Historical Profitability
6.08%
| SULPIZIO RICHARD | director | 26527 0.0181% | $5.84M | 1 | 1 | +6.08% |
RMD Institutional Investors: Active Positions
| Increased Positions | 483 | +60.6% | 9M | +9.98% |
| Decreased Positions | 335 | -42.03% | 5M | -6.02% |
| New Positions | 148 | New | 1M | New |
| Sold Out Positions | 70 | Sold Out | 2M | Sold Out |
| Total Postitions | 945 | +18.57% | 90M | +3.96% |
RMD Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $4.07M | 12.36% | 18.17M | +160,590 | +0.89% | 2024-12-31 |
| Blackrock, Inc. | $2.83M | 8.58% | 12.61M | +696,843 | +5.85% | 2024-12-31 |
| State Street Corp | $1.45M | 4.4% | 6.47M | +205,343 | +3.28% | 2024-12-31 |
| Bank Of New York Mellon Corp | $1.22M | 3.7% | 5.43M | -276,548 | -4.84% | 2024-12-31 |
| Geode Capital Management, Llc | $884,106.00 | 2.68% | 3.94M | +85,270 | +2.21% | 2024-12-31 |
| Morgan Stanley | $868,703.00 | 2.64% | 3.88M | -601,193 | -13.43% | 2024-12-31 |
| Invesco Ltd. | $521,174.00 | 1.58% | 2.33M | +566,046 | +32.18% | 2024-12-31 |
| Northern Trust Corp | $381,653.00 | 1.16% | 1.7M | +290,664 | +20.59% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $214,526.00 | 0.65% | 957,020 | +32,973 | +3.57% | 2024-12-31 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $213,986.00 | 0.65% | 954,612 | +212,201 | +28.58% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.